A Study to Test if TEV-53275 is Effective in Relieving Asthma
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of TEV-53275 administered
subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic
phenotype compared to placebo. A secondary objective is to evaluate the efficacy of TEV-53275
compared to placebo assessed by lung function, asthma symptoms, rescue medication use, and
quality of life measures. Another secondary objective is to evaluate the safety and
tolerability of TEV-53275 administered sc in adult participants with persistent asthma and an
eosinophilic phenotype compared with placebo, and lastly, to evaluate the immunogenicity of
TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic
phenotype.